{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:39:15Z","timestamp":1790087955659,"version":"4.0.1"},"reference-count":28,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1183\/13993003.01168-2024","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T09:02:04Z","timestamp":1724317324000},"page":"2401168","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Stepping down biologics in asthma: is it time to challenge the status quo?"],"prefix":"10.1183","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3167-1152","authenticated-orcid":false,"given":"Sandhya","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve N.","family":"Georas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"key":"2024102017341807000_64.2.2401168.1","unstructured":"Global Initiative for Asthma . Global Strategy for Asthma Management and Prevention. 2024. www.ginasthma.org"},{"key":"2024102017341807000_64.2.2401168.2","unstructured":"Global Initiative for Asthma . Difficult-To-Treat and Severe Asthma in Adolescent and Adult Patients. 2023. www.ginasthma.org"},{"key":"2024102017341807000_64.2.2401168.3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.anai.2022.06.012","article-title":"Biologic use and outcomes among adults with severe asthma treated by US subspecialists","volume":"129","author":"Panettieri","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102017341807000_64.2.2401168.4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JAA.S328653","article-title":"Real world biologic use and switch patterns in severe asthma: data from the international severe asthma registry and the US CHRONICLE study","volume":"15","author":"Menzies-Gow","year":"2022","journal-title":"J Asthma Allergy"},{"key":"2024102017341807000_64.2.2401168.5","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.jaip.2021.06.041","article-title":"Defining a severe asthma super-responder: findings from a Delphi process","volume":"9","author":"Upham","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102017341807000_64.2.2401168.6","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03130-2021"},{"key":"2024102017341807000_64.2.2401168.7","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2024102017341807000_64.2.2401168.8","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210017"},{"key":"2024102017341807000_64.2.2401168.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.026"},{"key":"2024102017341807000_64.2.2401168.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00396-2021"},{"key":"2024102017341807000_64.2.2401168.11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bcp.13453","article-title":"A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients","volume":"84","author":"Domingo","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2024102017341807000_64.2.2401168.12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.23822\/EurAnnACI.1764-1489.261","article-title":"Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?","volume":"56","author":"Korkmaz","year":"2024","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"2024102017341807000_64.2.2401168.13","doi-asserted-by":"crossref","first-page":"100703","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"Bolke","year":"2022","journal-title":"World Allergy Organ J"},{"key":"2024102017341807000_64.2.2401168.14","doi-asserted-by":"crossref","first-page":"e15933","DOI":"10.1111\/dth.15933","article-title":"Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: a retrospective analysis","volume":"35","author":"Patruno","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024102017341807000_64.2.2401168.15","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1111\/all.15439","article-title":"Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis","volume":"77","author":"Spekhorst","year":"2022","journal-title":"Allergy"},{"key":"2024102017341807000_64.2.2401168.16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/bjd.21628","article-title":"Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study","volume":"187","author":"Jendoubi","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024102017341807000_64.2.2401168.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00404-2024"},{"key":"2024102017341807000_64.2.2401168.18","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1016\/j.jaip.2019.04.019","article-title":"Association between pulmonary function and asthma symptoms","volume":"7","author":"Sullivan","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102017341807000_64.2.2401168.19","first-page":"CD010834","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102017341807000_64.2.2401168.20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102017341807000_64.2.2401168.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew464"},{"key":"2024102017341807000_64.2.2401168.22","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00296-020-04651-z","article-title":"Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis","volume":"40","author":"Vasconcelos","year":"2020","journal-title":"Rheumatol Int"},{"key":"2024102017341807000_64.2.2401168.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.30129"},{"key":"2024102017341807000_64.2.2401168.24","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","article-title":"Are we ready for asthma remission as a clinical outcome?","volume":"164","author":"Lugogo","year":"2023","journal-title":"Chest"},{"key":"2024102017341807000_64.2.2401168.25","doi-asserted-by":"crossref","unstructured":"Perez-de-Llano L , Scelo G , Tran TN , et al. Exploring definitions and predictors of severe asthma clinical remission post-biologic in adults. Am J Respir Crit Care Med 2024; in press [https:\/\/doi.org\/10.1164\/rccm.202311-2192OC].","DOI":"10.1164\/rccm.202311-2192OC"},{"key":"2024102017341807000_64.2.2401168.26","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024102017341807000_64.2.2401168.27","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2024102017341807000_64.2.2401168.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.03.013"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01168-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T07:22:12Z","timestamp":1740381732000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01168-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,22]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1183\/13993003.01168-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01168-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}